CA2775151C - Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations - Google Patents

Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations Download PDF

Info

Publication number
CA2775151C
CA2775151C CA2775151A CA2775151A CA2775151C CA 2775151 C CA2775151 C CA 2775151C CA 2775151 A CA2775151 A CA 2775151A CA 2775151 A CA2775151 A CA 2775151A CA 2775151 C CA2775151 C CA 2775151C
Authority
CA
Canada
Prior art keywords
polypeptide
domain
peptide
exosomes
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2775151A
Other languages
English (en)
French (fr)
Other versions
CA2775151A1 (fr
Inventor
Robert Zaine El Abiddine Mamoun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
University of Montpellier
Original Assignee
Centre National de la Recherche Scientifique
University of Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, University of Montpellier filed Critical Centre National de la Recherche Scientifique
Publication of CA2775151A1 publication Critical patent/CA2775151A1/fr
Application granted granted Critical
Publication of CA2775151C publication Critical patent/CA2775151C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2775151A 2009-09-24 2010-09-23 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations Active CA2775151C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0904576A FR2950350B1 (fr) 2009-09-24 2009-09-24 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
FR09/04576 2009-09-24
PCT/FR2010/052006 WO2011036416A1 (fr) 2009-09-24 2010-09-23 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations

Publications (2)

Publication Number Publication Date
CA2775151A1 CA2775151A1 (fr) 2011-03-31
CA2775151C true CA2775151C (fr) 2019-01-22

Family

ID=42107419

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2775151A Active CA2775151C (fr) 2009-09-24 2010-09-23 Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations

Country Status (6)

Country Link
US (1) US9611481B2 (cg-RX-API-DMAC7.html)
EP (1) EP2480672B8 (cg-RX-API-DMAC7.html)
JP (1) JP5932647B2 (cg-RX-API-DMAC7.html)
CA (1) CA2775151C (cg-RX-API-DMAC7.html)
FR (1) FR2950350B1 (cg-RX-API-DMAC7.html)
WO (1) WO2011036416A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512680A (ja) * 2013-03-15 2016-05-09 ノババックス,インコーポレイテッド ピコルナウイルス(Picornavirus)タンパク質の発現増強
US10538570B2 (en) * 2013-09-30 2020-01-21 Northwestern University Targeted and modular exosome loading system
PL228341B1 (pl) * 2014-04-21 2018-03-30 Bio Ventures Inst Spolka Z Ograniczona Odpowiedzialnoscia Sposób uzyskiwania białka poliepitopowego oraz wektor DNA do realizacji tego sposobu
WO2016138525A1 (en) * 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
US10702581B2 (en) 2015-05-04 2020-07-07 Ilias Biologics Inc. Compositions containing protein loaded exosome and methods for preparing and delivering the same
AU2017335084B2 (en) * 2016-09-30 2023-06-29 Ilias Biologics Inc. Compositions containing protein loaded exosome and methods for preparing and delivering the same
EP4059510B1 (en) 2018-11-16 2025-05-21 Lonza Sales AG Engineered extracellular vesicles and uses thereof
IT201900000651A1 (it) 2019-01-16 2019-04-16 Pastore Lucio Tecnologia di trasferimento genico
KR20210141554A (ko) 2019-03-21 2021-11-23 코디악 바이오사이언시즈, 인크. 세포외 소포 접합체 및 이의 용도
WO2020215010A1 (en) 2019-04-17 2020-10-22 Codiak Biosciences, Inc. Compositions of exosomes and aav
EP3973969A4 (en) * 2019-09-02 2023-07-12 Kyungpook National University Industry-Academic Cooperation Foundation COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER USING IL-2 EXTRACELLULAR SURFACE EXPRESSION VESICLES AS AN ACTIVE AGENT
WO2021144363A1 (en) 2020-01-14 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic reactivity of a peptide mimicking the glycan loop of flaviviruses envelope protein
JP7562682B2 (ja) * 2020-01-27 2024-10-07 マントラ バイオ,インコーポレイテッド キメラ小胞局在化部分を含む非天然発生の小胞、その産生方法、およびその使用
KR20220139926A (ko) 2020-02-05 2022-10-17 다이아뎀 바이오쎄라퓨틱스 인크 인공 시냅스
WO2021184021A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting pmp22
EP4138907A4 (en) * 2020-04-20 2024-08-21 The General Hospital Corporation IMMUNOGENIC COMPOSITION OF CORONAVIRUS WITH EPITOPES HAVING HIGH NETWORK SCORE
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
CN116194462B (zh) * 2020-08-11 2025-07-18 庆北大学校产学协力团 选择性结合癌细胞来源外泌体的肽及其用途
EP3973985A1 (en) * 2020-09-29 2022-03-30 Ciloa Extracellular vesicles harboring a spike protein, nucleic acids for producing the same, and method of immunizing a subject against sars-cov-2 using the same
CN113480666B (zh) * 2021-08-13 2024-01-26 郑州伊美诺生物技术有限公司 Ca153融合蛋白及其制备方法和ca153检测质控品或校准品
CA3255140A1 (en) 2022-05-20 2023-11-23 Ciloa REVERSIBLE LOADING OF PROTEINS IN THE LUMINUM OF EXTRACELLULAR VESICLES
EP4612190A2 (en) * 2022-11-02 2025-09-10 Pioneer Biolabs, LLC Systems and methods for single cell detection of protein secretion
CN121646610A (zh) * 2023-06-05 2026-03-10 希洛欧公司 嵌合多肽、包含嵌合多肽的胞外囊泡及其用途
WO2026022863A1 (en) * 2024-07-25 2026-01-29 Christian Medical College Extracellular vesicles and uses thereof for targeted delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1417229B1 (en) * 2001-08-17 2011-06-15 Exothera L.L.C. Methods and compounds for the targeting of protein to exosomes
JP2005528091A (ja) 2002-03-14 2005-09-22 アノシス・インコーポレーテッド T細胞由来小胞の機能化、および免疫原性医薬組成物を製造するためのその使用
WO2004073319A2 (en) * 2003-02-14 2004-08-26 Anosys, Inc. Methods and compounds for raising antibodies and for screening antibody repertoires
FR2928926B1 (fr) 2008-03-18 2015-08-21 Centre Nat Rech Scient Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes

Also Published As

Publication number Publication date
WO2011036416A1 (fr) 2011-03-31
EP2480672A1 (fr) 2012-08-01
CA2775151A1 (fr) 2011-03-31
US9611481B2 (en) 2017-04-04
US20120321653A1 (en) 2012-12-20
FR2950350B1 (fr) 2013-12-13
FR2950350A1 (fr) 2011-03-25
JP2013505713A (ja) 2013-02-21
EP2480672B8 (fr) 2017-03-22
JP5932647B2 (ja) 2016-06-08
EP2480672B1 (fr) 2016-12-28

Similar Documents

Publication Publication Date Title
EP2480672B1 (fr) Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
CA2718868C (fr) Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes
US10577397B2 (en) Methods and compositions for protein delivery
US20230151385A1 (en) Selectable marker proteins, expression vectors, engineered cells and extracellular vesicles for the production of virus-like particles for therapeutic and prophylactic applications
BE1023087B1 (fr) Antigenes du cytomegalovirus et leurs utilisations
Bui et al. Virus-free method to control and enhance extracellular vesicle cargo loading and delivery
KR20210043574A (ko) 푸소좀 조성물 및 이의 용도
WO2017083423A1 (en) Methods and compositions for modulating aav infection
JP7420558B2 (ja) 自己不活性化ウイルスベクター
CA3207878A1 (en) Coronavirus spike protein designs, compositions and methods for their use
CA3254064A1 (en) Immunogenic compositions against SARS-CoV-2
WO2024112359A1 (en) Genetic enhancement of exosome production
KR20220117091A (ko) 생체내 세포에서 합성 및 분비되고 세포로 투과하는 관심 폴리펩타이드를 코딩하는 발현카세트 및 이의 용도
Jia et al. Highly efficient method for intracellular delivery of proteins mediated by cholera toxin-induced protein internalization
US12502437B2 (en) Compositions and methods for therapeutic delivery
US20260097115A1 (en) Immunogenic compositions and use thereof
Bertrand Understanding the mechanisms of entry of Jaagsiekte sheep retrovirus
JPH05227971A (ja) 細菌毒素−抗原結合体由来の細胞性免疫ワクチン用の組換えdna配列及びプラスミドとその使用方法
Apte Determinants of retrovirus and alphavirus envelope protein processing and virion incorporation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150825

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - SMALL

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240913

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240913

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240913

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - SMALL

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250901

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250901